Colorectal Cancer Therapeutics in Asia-Pacific Markets

to 2020 - Improved Regional Healthcare Access to Drive

Uptake of High-Cost Targeted Therapies
st

On 1 December 2014

Summary
The leading business intelligence provider, has released its latest research, "Colorectal Cancer
Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive
Uptake of High-Cost Targeted Therapies", which provides in-depth insights into the indication.
It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific
(APAC) region, which comprises Australia, China, India and Japan. It also covers disease
epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials
including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer
(CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is
expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $1.9 billion in 2020.
The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the
purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access
to these more expensive agents improves. The moderate uptake of late-stage pipeline products
panitumumab and Xilonix, following their expected approval, is expected to drive additional
growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also
contribute. An increasingly aging population and a year-on-year increase in the number of
incident cases will provide an additional boost. However, the recent implementation of a price
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access,
penetration and price erosion due to generic dominance, especially in India, stand to curtail the
APAC CRC market.

You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-colorectal-cancer-therapeutics-in-asia-pacific-markets-139521

Scope
The report analyzes treatment usage patterns, market characterization, the pipeline, and key
licensing and co-development deals in the four APAC markets of Australia, China, India and
Japan. It includes - A brief introduction to CRC, including the diseases pathogenesis, etiology, diagnosis and
treatment algorithms
- In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy,
treatment patterns and strengths/weaknesses and including a heat map that compares the
drugs in terms of safety and efficacy
- A comprehensive review of the pipeline for CRC, including individual analysis of a number of
late-stage pipeline drugs that are likely to enter the market during the forecast period; the
pipeline is analyzed on the basis of Phase distribution, molecule type, program type,
mechanism of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and
program failure rate for each molecule type
- Multi-scenario forecast data of the market to 2020, taking into account how the market may
be affected by the introduction of new drugs, the expiry of key patents on current drugs and
the changes in disease epidemiology across the key developed markets
- Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that have occurred in the CRC
market since 2006

Reasons to buy
The report will enhance your decision-making capability by allowing you to Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

- Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
- Examine detailed profiles of promising pipeline products and gain an insight into how they are
likely to compete in the market and who their main competitors will be
- Follow the trends in CRC clinical trial size and duration in relation to industry averages and
assess the potential risk of future developmental programs according to mechanism of action
by considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the CRC market over the forecast period,
identify which countries are expected to make the biggest contribution to this growth, and
devise a more effective country strategy through an understanding of key drivers and barriers
in the CRC market
- Accelerate and strengthen your market position by identifying key companies for strategic
partnerships

Other industries we cover:

Advertising and Media

Automotive and Parts
Consumer Goods
Healthcare and Medical
Finance and Banking
Food and Beverages
Travel and Tourism
Textiles and Clothing
SWOT Analysis

Discounts on Market Research Reports till 31st December, 2014

For more inquiries, contact at +91 - 998 729 5242 /
contact@jsbmarketresearch.com
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Table of Content
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Colorectal Cancer 8
2.2 Symptoms 8
2.3 Epidemiology 8
2.4 Pathophysiology 9
2.4.1 Histology 9
2.4.2 Genetic Basis 9
2.4.3 Etiology 9
2.5 Diagnosis 10
2.5.1 Digital Rectal Examination 11
2.5.2 Fecal Occult Blood Test 11
2.5.3 Flexible Sigmoidoscopy 11
2.5.4 Colonoscopy 11
2.5.5 Virtual Colonoscopy 12
2.5.6 Double Contrast Barium Enema 12
2.6 Prognosis and Disease Staging 12
2.7 Treatment Options 14
2.7.1 Surgery and Radiation Therapy 15
2.7.2 Chemotherapy 15
2.7.3 Targeted Therapies 15
2.7.4 Resistance to Pharmacological Therapies 16
2.7.5 Treatment Guidelines 17
3 Marketed Products 20
3.1 Key Marketed Products 20
3.1.1 Immunotherapies 20
3.1.2 Targeted Therapies 23
3.2 Hyperthermic Intraperitoneal Chemotherapy 28
3.3 Heat Map for Marketed Products 29
4 Pipeline Analysis 31
4.1 Overall Pipeline 31
4.1.1 Pipeline Analysis by Molecule Type 32
4.1.2 Pipeline Analysis by Mechanism of Action 33
4.2 Clinical Trials 35
4.2.1 Failure Rate 35
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

4.2.2 Clinical Trial Size 37

4.2.3 Duration 39
4.3 Promising Drug Candidates in Pipeline 41
4.3.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) Taiho Pharmaceutical 41
4.3.2 Cyramza ramucirumab Eli Lilly and Company 42
4.3.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) Taiho Pharmaceutical 42
4.3.4 CPP-1X (eflornithine hydrochloride) + sulindac Cancer Prevention Pharmaceuticals 43
4.3.5 MelCancerVac DanDrit Biotech 44
4.3.6 Xilonix XBiotech 45
4.3.7 Nintedanib Boehringer Ingelheim 45
5 Market Forecast to 2020 47
5.1 Asia-Pacific Market 47
5.1.1 Treatment Use Patterns 47
5.1.2 Market Size 47
5.2 Australia 48
5.2.1 Treatment Use Patterns 48
5.2.2 Annual Cost of Therapy 49
5.2.3 Market Size 50
5.3 India 51
5.3.1 Treatment Use Patterns 51
5.3.2 Annual Cost of Therapy 52
5.3.3 Market Size 53
5.4 China 54
5.4.1 Treatment Use Patterns 54
5.4.2 Annual Cost of Therapy 55
5.4.3 Market Size 56
5.5 Japan 57
5.5.1 Treatment Use Patterns 57
5.5.2 Annual Cost of Therapy 58
5.5.3 Market Size 59
5.6 Drivers and Barriers 60
5.6.1 Drivers 60
5.6.2 Barriers 62
6 Deals and Strategic Consolidations 63
6.1 Licensing Agreements 63
6.1.1 Major Licensing Deals 64
6.2 Co-development Agreements 65
6.2.1 Major Co-development Agreements 67
7 Appendix 68
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

7.1 All Pipeline Drugs by Phase 68

7.1.1 Discovery 68
7.1.2 Preclinical 70
7.1.3 IND/CTA-Filed 75
7.1.4 Phase I 76
7.1.5 Phase II 80
7.1.6 Phase III 85
7.2 Market Forecasts to 2020 86
7.2.1 Asia-Pacific 86
7.2.2 Australia 86
7.2.3 India 86
7.2.4 China 87
7.2.5 Japan 87
7.3 Market Definitions 87
7.4 Abbreviations 87
7.5 References 91
7.6 Research Methodology 94
7.6.1 Coverage 94
7.6.2 Secondary Research 94
7.6.3 Primary Research 95
7.6.4 Therapeutic Landscape 95
7.6.5 Geographical Landscape 98
7.6.6 Pipeline Analysis 98
7.7 Expert Panel Validation 98
7.8 Contact Us 98
7.9 Disclaimer 98

List Of Tables
Table 1 Colorectal Cancer Therapeutics, Global, TNM Staging, 2013 14
Table 2 Surgical Options for Colorectal Cancer 15
Table 3 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014 68
Table 4 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014 70
Table 5 Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2013 75
Table 6 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014 76
Table 7 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014 80
Table 8 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014 85
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Table 9 Colorectal Cancer Therapeutics, Asia-Pacific, Forecast Data, 20132020 86

Table 10 Colorectal Cancer Therapeutics, Australia, Forecast Data, 20132020 86
Table 11 Colorectal Cancer Therapeutics, India, Forecast Data, 20132020 86
Table 12 Colorectal Cancer Therapeutics, China, Forecast Data, 20132020 87
Table 13 Colorectal Cancer Therapeutics, Japan, Forecast Data, 20132020 87

List Of Figures
Figure 1: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology
Treatment Guidelines (Colorectal Cancer at Stage I to III) 17
Figure 2: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology
Treatment Guidelines (Colorectal Cancer at Stage IV) 18
Figure 3: Colorectal Cancer Therapeutics, Global, Heat Map (Marketed Products) 30
Figure 4: Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and
Program Type, 2013 31
Figure 5: Colorectal Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of
Development, 2013 32
Figure 6: Colorectal Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of
Development, 2013 34
Figure 7: Colorectal Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2013 36
Figure 8: Colorectal Cancer Therapeutics, Global, Clinical Trial Size, 2013 38
Figure 9: Colorectal Cancer Therapeutics, Global, Clinical Trial Duration (months), 2013 40
Figure 10: Colorectal Cancer Therapeutics, Asia-Pacific, Treatment Use Patterns (000) ,2013
2020 47
Figure 11: Colorectal Cancer Therapeutics, Asia-Pacific, Market Size ($bn), 20132020 48
Figure 12: Colorectal Cancer Therapeutics, Australia, Treatment Use Patterns (000), 20132020
49
Figure 13: Colorectal Cancer Therapeutics, Australia, Annual Cost of Therapy ($), 20132020 50
Figure 14: Colorectal Cancer Therapeutics, Australia, Market Size ($m), 20132020 51
Figure 15: Colorectal Cancer Therapeutics, India, Treatment Use Patterns (000), 20132020 52
Figure 16: Colorectal Cancer Therapeutics, India, Annual Cost of Therapy ($), 20132020 53
Figure 17: Colorectal Cancer Therapeutics, India, Market Size ($m), 20132020 54
Figure 18: Colorectal Cancer Therapeutics, China, Treatment Use Patterns (000), 20132020 55
Figure 19: Colorectal Cancer Therapeutics, China, Annual Cost of Therapy ($), 20132020 56
Figure 20: Colorectal Cancer Therapeutics, China, Market Size ($m), 20132020 57
Figure 21: Colorectal Cancer Therapeutics, Japan, Treatment Use Patterns (000), 20132020 58
Figure 22: Colorectal Cancer Therapeutics, Japan, Annual Cost of Therapy ($), 20132020 59
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Figure 23: Colorectal Cancer Therapeutics, Japan, Market Size, 20132020 60

Figure 24: Colorectal Cancer Therapeutics, Global, Licensing Deals by Geography, 20062014 63
Figure 25: Colorectal Cancer Therapeutics, Global, Licensing Deals by Phase, Value, Mechanism
of Action, 20062014 64
Figure 26: Colorectal Cancer Market, Global, Co-development Deals by Geography and by
Value, 20062014 66
Figure 27: GBI Research Market Forecasting Model 97

Report Price:
Licence Type

Price

PDF

$ 4995

Site Licence

$ 9990

Enterprise Wide Licence

$ 14985

Related Reports:
Nexgen Pharma, Inc. - Strategic SWOT Analysis Review
Orion HealthCorp, Inc. - Strategic SWOT Analysis Review
EBEWE Pharma Ges.m.b.H. Nfg.KG - Strategic SWOT Analysis Review
Adenium Biotech ApS - Product Pipeline Review 2014
Agilvax, Inc. - Product Pipeline Review - 2014
Agios Pharmaceuticals, Inc. - Product Pipeline Review - 2014
Angita B.V. - Product Pipeline Review - 2014
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/

Basilea Pharmaceutica AG - Product Pipeline Review 2014

BeiGene (Beijing) Co., Ltd - Product Pipeline Review - 2014
Beta Pharma, Inc. - Product Pipeline Review 2014

You can order this report by calling on +91 - 998 7295 242 or mail us
your contact details at contact@jsbmarketresearch.com

About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along
with providing in-depth analysis though reports, JSB market research also provides regular
updates of the market though newsletters. Our reports are a well-researched work of market
researchers with an extensive knowledge and a good level of market experience.

To know more on Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020

- Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted
Therapies
http://www.jsbmarketresearch.com/healthcare-medical/r-colorectal-cancertherapeutics-in-asia-pacific-markets-139521

Email ID- contact@jsbmarketresearch.com

Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/